CTRI/2024/03/063624尚未招募3 期
A randomized open label trial comparing the efficacy and safety of oral Prednisolone versus intravenous Methylprednisolone pulse therapy in Systemic Lupus Erythematosus. - NI
IMS and SUM Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients aged 18 years and above with SLEDAI score more than 10 fulfilling the EULAR criteria
排除标准
- •1. Patients on any treatment within last 3 months
- •2. Patients having features of other connective tissue diseases
- •3. Patients with other autoimmune conditions
- •4. Patients with pre-existing chronic renal failure, previous
- •malignancy, and liver dysfunction, within six months prior
- •to randomization.
- •5. Patients with previously documented severe toxicity to
- •immunosuppressive drugs.
- •6. Patients with active acute or chronic infections.
- •7. Pregnancy and lactation.
研究者
相似试验
尚未招募
3 期
An interventional study to see outcome by comparing efficiency and safety of two drugs i.e. of levetiracetam versus oxcarbazepine in management of bipolar disorder.CTRI/2024/04/065780ttar Pradesh University of Medical sciences Department of Pharmacology and Psychiatry
已完成
3 期
Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study)NL-OMON55657Grupo Espanol de Tumores Neuroendocrinos (GETNE)22
进行中（未招募）
1 期
Randomized not blinded clinical trial to compare two sequences oftreatment: STZ-5FU followed by everolimus or everolimus followed by STZ-5FU upon progression in advanced progressive pancreatic neuroendocrinetumors (SEQTOR study)advanced progressive pNETsMedDRA version: 17.1Level: PTClassification code 10067517Term: Pancreatic neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000726-66-FRGrupo Español de Tumores Neuroendocrinos (GETNE)180
进行中（未招募）
1 期
Randomized open label study to compare the efficacy and safetyof everolimus followed by chemotherapy with STZ-5FU upon progression orthe reverse sequence, chemotherapy with STZ-5FU followed by everolimusupon progression, in advanced progressive pNETs(SEQTOR study)advanced progressive pNETsMedDRA version: 20.1Level: PTClassification code 10067517Term: Pancreatic neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000726-66-DKGrupo Español de Tumores Neuroendocrinos (GETNE)140
进行中（未招募）
不适用
Randomized not blinded clinical trial to compare two sequences of treatment: STZ-5FU followed by everolimus or everolimus followed by STZ-5FU upon progression in advanced progressive pancreatic neuroendocrine tumors (SEQTOR study)advanced progressive pNETsMedDRA version: 17.0Level: PTClassification code 10067517Term: Pancreatic neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000726-66-ITGrupo Español de Tumores Neuroendocrinos (GETNE)180